Key Points
- Maricel Apuli, BridgeBio's CAO, sold 2,000 shares on April 30 at an average price of $71.58 for proceeds of $143,160 under a pre‑arranged Rule 10b5‑1 plan, reducing her stake by 1.47% to 134,115 shares (≈$9.6M).
- BridgeBio is heavily institutionally owned (99.85%) with recent large stakes added by firms like Price T. Rowe and Janus Henderson, while analysts are broadly bullish (24 Buys, 1 Sell) and the consensus price target is about $87.71, with some targets raised as high as $102.00.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 2,000 shares of the firm's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $71.58, for a total transaction of $143,160.00. Following the sale, the chief accounting officer owned 134,115 shares in the company, valued at approximately $9,599,951.70. The trade was a 1.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maricel Apuli also recently made the following trade(s):
- On Tuesday, February 17th, Maricel Apuli sold 510 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10.
BridgeBio Pharma Trading Up 0.6%
Shares of BBIO stock opened at $68.99 on Tuesday. BridgeBio Pharma, Inc. has a 1 year low of $31.77 and a 1 year high of $84.94. The firm's fifty day moving average price is $71.28 and its two-hundred day moving average price is $71.05. The firm has a market capitalization of $13.51 billion, a P/E ratio of -18.25 and a beta of 1.02.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million for the quarter, compared to analysts' expectations of $150.71 million. During the same quarter in the prior year, the firm earned ($1.40) EPS. The company's revenue was up 2521.2% on a year-over-year basis. As a group, equities research analysts forecast that BridgeBio Pharma, Inc. will post -2.05 EPS for the current fiscal year.
Institutional Trading of BridgeBio Pharma
Hedge funds and other institutional investors have recently modified their holdings of the stock. Brooklands Fund Management Ltd acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $210,348,000. Price T Rowe Associates Inc. MD raised its stake in BridgeBio Pharma by 144.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company's stock worth $292,862,000 after purchasing an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC raised its stake in BridgeBio Pharma by 25.8% in the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company's stock worth $841,349,000 after purchasing an additional 2,259,378 shares in the last quarter. Norges Bank acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $116,802,000. Finally, Wellington Management Group LLP raised its stake in BridgeBio Pharma by 130.4% in the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company's stock worth $179,654,000 after purchasing an additional 1,329,537 shares in the last quarter. Institutional investors own 99.85% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have issued reports on BBIO shares. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an "overweight" rating in a research note on Friday, February 13th. Raymond James Financial set a $89.00 price target on shares of BridgeBio Pharma and gave the company an "outperform" rating in a research note on Thursday, February 12th. Barclays reiterated an "overweight" rating on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. Truist Financial lifted their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a "buy" rating in a research note on Wednesday, April 29th. Finally, Morgan Stanley lifted their price objective on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Twenty-four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $87.71.
Read Our Latest Research Report on BBIO
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
